HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis

Journal of Neurology

Volumn 250, Issue 9, 2003, Pages 1099-1106

  Zivadinov, Robert ^a,d   Uxa, Laura ^b   Zacchi, Tullio ^b   Nasuelli, Davide ^a   Ukmar, Maja ^c   Furlan, Christina ^c   Pozzi Mucelli, Roberto ^c   Tommasi, Maria Antonietta ^a   Locatelli, Laura ^a   Ulivi, Sheila ^b   Bratina, Alessio ^a   Bosco, Antonio ^a   Grop, Attillio ^a   Cazzato, Giuseppe ^a   Zorzon, Marino ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Dept of Transfusion Medicine ^*  (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

HLA; MRI; Multiple sclerosis

Indexed keywords

GENE PRODUCT; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; OLIGONUCLEOTIDE;

ADULT; ALLELISM; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; GENE LOCUS; GENOTYPE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

ADULT; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; FEMALE; GENOTYPE; HLA ANTIGENS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ODDS RATIO; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 0141627437     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0164-7     Document Type: Article

References (70)

1. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G (1999) A prospective study on the natural history of multiple sclerosis: clues to conduct and interpretation of clinical trials. J Neurol Sci 168:96-106
2. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A (2000) Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 48:211-219
3. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD (2001) APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 56:312-316
4. Compston DA (1999) The genetic epidemiology of multiple sclerosis. Phil Trans R Soc Lond B 354:1623-1634
5. Compston DA, Batchelor JR, McDonald WI (1976) B lymphocyte alloantigens associated with multiple sclerosis. Lancet 2:1261-1265
6. Coraddu F, Reyes-Yanez MP, Parra A, Gray J, Smith SI, Taylor CJ, Compston DA (1998) HLA association with multiple sclerosis in Canary Islands. J Neuroimmunol 87:30-35
7. Crusius JB, Pena AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, Polman CH (1995) Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 346:979
8. Cullen CG, Middleton D, Savage DA, Hawkins S (1991) HLA-DR and DQ DNA genotyping in multiple sclerosis patients in Northern Ireland. Hum Immunol 30:1-6
9. de la Concha EG, Arroyo R, Crusius JB, Campillo JA, Martin C, Varela de Seijas E, Pena AS, Claveria LE, Fernandez-Arquero M (1997) Combined effect of HLA-DRB1*1501 and interleukin-1-receptor antagonist gene allele-2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 80:172-178
10. Duquette P, Decary F, Pleines J, Boivin D, Lamoureux G, Cosgrove JB, Lapierre Y (1985) Clinical sub-groups of multiple sclerosis in relation to HLA:DR alleles as possible markers of disease progression. Can J Neurol Sci 12:106-110
11. Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, Wingerchuk DM, Bakerville J, Rice GP (2000) The natural history of multiple sclerosis: a geographically based study: 8. Familial multiple sclerosis. Brain 123:641-649
12. Engell T, Raun NE, Thomsen M, Platz P (1982) HLA and heterogeneity of multiple sclerosis. Neurology 32:1043-1046
13. Fazekas S, Strasser-Fuchs S, Kolleger H, Berger T, Kristoferitisch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R (2001) Apolipoprotein E epsilon4 is associated with rapid progression of multiple sclerosis. Neurology 57:853-857
14. Fazekas F, Strasser-Fuchs S, Schmidt H, Enzinger C, Ropele S, Lechner A, Flooh E, Schmidt R, Hartung HP (2000) Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurology Neurosurg Psychiatry 69:25-28
15. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, Scotti G, Comi G (1995) A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 45:478-482
16. Finstad Harbo H, Celius EG, Vartdal F, Spurkland A (1999) CTLA-4 Promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 53:106-110
17. Francis DA, Thompson AJ, Brookes P, Davey N, Lechler RI, McDonald WI, Batchelor JR (1991) Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ. Hum Immunol 32:119-124
18. Frederiksen JL, Madsen HO, Ryder LP, Larsson HB, Morling N, Svejgaard A (1997) HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 54:76-80
19. Grimaud J, Lai M, Thorpe J, Adeleine P, Wang L, Barker GJ, Plummer DL, Toffs PS, McDonald WI, Miller DH (1996) Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imag 14:495-505
20. Haines JL, Terwedow HA, Burgess K (1998) Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Mol Genet 7:1229-1234
21. Hauser SL, Oksenberg JR, Lincoln R, Garovoy J, Beck RW, Cole SR, Moke PS, Kip KE, Gal RL, Long DT (2000) Interaction between HLA-DR2 and abnormal MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology 54:1859-1861
22. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, Roxburgh R, Coraddu F, Smith S, Compston DA (2002) HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 72:184-187
23. Hillert J, Kall T, Olerup O, Soderstrom M (1996) Distribution of HLA-Dw2 in optic neuritis and multiple sclerosis indicates heterogeneity. Acta Neurol Scand 94:161-166
24. Jersild C, Swejgaard A, Fog T (1973) Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 2:1221-1225
25. Kantarci OH, de Andrade M, Weinshenker G (2002) Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123:144-159
26. Kelly MA, Cavan DA, Penny MA, Mijovic CH, Jenkins D, Morrissey S, Miller DH, Barnett AH, Francis DA (1993) The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum Immunol 37:185-191
27. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
28. Ligers A, Xu C, Saarinen S, Hiller TJ, Olerup O (1999) The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 97:182-190
29. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lasmann H (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases. Brain 122:2279-2295
30. Lucchinetti C, Bruck W, Rodriguez M, Lasmann H (1996) Distinct patterns of multiple sclerosis pathology indicates hetereogeneity in pathogenesis. Brain Pathol 6:259-274
31. Luomala M, Elovaara I, Ukkonen M, Koivula T, Lehtimaki T (2001) The combination of HLA-DR1 and HLA-DR53 protects against MS. Neurology 56:383-385
32. Madigrand M, Oger JJ, Fauchet R, Sabouraud O, Genetet B (1982) HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 53:519-529
33. Mann CLA, Davies MB, Stevenson VL, Leary SM, Boggild MD, Ko Ko C, Jones PW, Fryer AA, Strange RC, Thompson AJ, Hawkins CP (2002) Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol 129:197-204
34. Marrosu MG, Murru MR, Costa G, Murru R, Muntoni F, Cucca F (1998) DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 7:1235-1237
35. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J (2000) HLA-DR 15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48:211-219
36. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
37. McDonell GV, Mawhinney H, Graham CA, Hawkins SA, Middleton D (1999) A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis J Neurol Sci 165:77-83
38. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE (1992) Using gadolinium-enhanced magnetic resonance imaging to monitor disease activity in multiple sclerosis. Ann Neurol 32:758-766
39. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psyhiatry 54:683-688
40. Mirsattari SM, Johnston JB, McKenna R, Del Bigio MR, Orr P, Ross RT, Power C (2001) Aboriginals with multiple sclerosis. HLA types and predominance of neuromyelitis optica. Neurology 56:317-323
41. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116:135-146
42. Najim Al-Din AS, Kurdi A, Mubaidin A, El-Khateeb M, Khalil RW, Wriekat AL (1996) Epidemiology of multiple sclerosis in Arabs in Jordan: a comparative study between Jordanians and Palestinians. J Neurol Sci 135:162-167
43. Olerup O, Hillert J (1991) HLA class I-associated susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 38:1-15
44. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E, Carlsson B, Wallin J (1989) Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct entities. Proc Natl Acad Sci USA 86:7113-7117
45. Pina MA, Ara JR, Lasierra P, Modrego PJ, Larrad L (1999) Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain. Neuroepidemiol 18:203-209
46. Petrowsky N, Harrison LC (1997) HLA class II-associated polymorphism of interferon-gamma production. Implications for HLA-disease associations. Hum Immunol 53:12-16
47. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 12:227-231
48. Runmarker B, Martinsson T, Wahlstrom J, Andersen O (1994) HLA and prognosis in multiple sclerosis. J Neurol 241:385-390
49. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Ornek I, Vaughan R, Eraksoy M (1997) HLA-DR and DQ associations with multiple sclerosis in Turkey. Hum Immunol 55:59-65
50. Sawcer SJ, Goodfellow PN, Compston DA (1997) The genetic analysis of multiple sclerosis. Trends Genet 3:234-239
51. Schreiber K, Oturai AB, Ryder LP, Madsen HO, Jorgensen OS, Svejgaard A, Sorensen PS (2002) Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 8:295-298
52. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P (2000) CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102:98-96
53. Sinha AA, Bell RB, Steinman L, McDewitt HO (1991) Oligonucleotide dot-blot analysis of HLA-DQ beta alleles associated with multiple sclerosis. J Neuroimmunol 32:61-65
54. Soderstrom M, Lindqvist M, Hillert J, Kall TB, Link H (1994) Optic neuritis: findings on MR1, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol 241:391-397
55. Soderstrom M, Ya-Ping J, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50:708-714
56. Spurkland A, Ronningen KS, Vandvik B, Thorsby E,Vartdal F (1991) HLA-DQA1 and HLA-DQB1 genes may jointly determine susceptibility to develop multiple sclerosis. Hum Immunol 30:69-75
57. Takacs K, Kalman B, Gyodi E, Tauszik T, Palffy G, Kuntar L, Guseo A, Nagy C, Petranyi G (1990) Association between the lack of HLA-DQw6 and the low incidence of multiple sclerosis in Hungarian Gypsies. Immunogenetics 31:383-385
58. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, McDonald WI (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53-62
59. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831-835
60. Thompson AJ, Miller D, Youl B, Mac-Manus D, Moore S, Kingsley D, Kendall B, Feinstein A, McDonald WI (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42:60-63
61. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M Montalban X, De Sa J (1997) Primary progressive multiple sclerosis. Brain 12:1085-1096
62. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin echo MRI in multiple sclerosis. Neurology 50:1282-1288
63. Weatherby SJM, Thomson W, Pepper L, Donn R, Worthington J, Mann CLA, Davies MB, Fryer AA, Boggild MD, Young CA, Jones PW, Strange RE, Ollier WER, Hawkins CP (2001) HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 248:304-310
64. Weinshenker BG, Bass B, Rice GP (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133-136
65. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB, Rodriguez M (1998) Major histocompatibility complex class II alleles and the course and outcome of MS: a popoulation-based study. Neurology 51:742-747
66. Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS (1997) Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 49:378-385
67. Winchester R, Ebers G, Fu SM, Espinosa L, Zabriskie J, Kunkel HG (1975) B-cell alloantigen Ag7a in multiple sclerosis. Lancet 2:814
68. Yamasaki K, Horiuchi I, Minohara M, Kawano Y, Ohyagi Y, Yamada T, Mihara F, Ito H, Nishimura Y, Kira J (1999) HLA-DPB1*0501-associated opticospinal multiple sclerosis. Clinical, neuroimaging and immunogenetic studies. Brain 122:1689-1696
69. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Magnetic resonance imaging techniques and cognitive impairment in early phase of relapsing-remitting multiple sclerosis. Neuroradiology 43:272-278
70. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Effects of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis. Neurology 57:1239-1247